Position in NVS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$9,251,456
+$6,978,118 QoQ
Shares Held
60,566
+267.3% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2021
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026XTX Topco Ltd holds $56,692,973 across 12 Drug Manufacturers - General names. NVS ranks #1 (16.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NVS |
Novartis AG
This page
|
60,566 | $9,251,456 | |
| 2 | JNJ |
Johnson & Johnson
|
36,844 | $9,006,147 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
60,352 | $8,411,258 | |
| 4 | PFE |
Pfizer Inc
|
275,144 | $7,726,043 | |
| 5 | AMGN |
Amgen Inc
|
19,756 | $6,951,148 | |
| 6 | ABBV |
AbbVie Inc.
|
26,692 | $5,805,243 | |
| 7 | MRK |
Merck & Co., Inc.
|
34,803 | $4,186,452 | |
| 8 | LLY |
ELI LILLY & Co
|
4,218 | $3,879,589 |
All Filings in NVS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,251,456 | 60,566 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $2,273,338 | 16,489 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $721,606 | 5,627 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $1,114,865 | 9,213 | Shares | Defined | 2025-08-12 | |
| 2025-03-31 | $254,285 | 2,281 | Shares | Defined | 2025-05-08 | |
| 2024-12-31 | $1,009,980 | 10,379 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $3,510,295 | 30,519 | Shares | Defined | 2024-11-14 | |
| 2023-12-31 | $456,283 | 4,519 | Shares | Defined | 2024-02-13 | |
| 2022-09-30 | $296,362 | 3,899 | Shares | Defined | 2022-11-14 | |
| 2021-12-31 | $522,370 | 5,972 | Shares | Defined | 2022-02-11 | |
| No filing history on record for this holder in this stock. | ||||||